DealsJun 8, 2026, 07:11 AM
Tonix Pharmaceuticals Expands TONMYA Coverage to 52M Lives
AI Summary
Tonix Pharmaceuticals Holding Corp. announced a new agreement with a group purchasing organization (GPO) that expands commercial coverage for its drug TONMYA®. This deal, effective June 1, 2026, adds approximately 17 million U.S. commercial lives, bringing the total commercial coverage to about 52 million lives. TONMYA is also available to approximately 75 million Medicaid beneficiaries, with ongoing discussions for Medicare coverage.
Key Highlights
- Tonix Pharmaceuticals secured a second commercial payer agreement for TONMYA® with a GPO.
- This agreement adds approximately 17 million U.S. commercial lives to TONMYA's coverage.
- Total commercial coverage for TONMYA now extends to approximately 52 million U.S. lives.
- TONMYA is the first new fibromyalgia medicine for adults approved by the FDA in over 15 years.
- The drug is also available under Medicaid for approximately 75 million beneficiaries.
- Discussions with Medicare for coverage are ongoing.
Price Impact
More from TNXP